Gain Value of 99Tcm-MIBI SPECT/CT Tomography in Evaluating the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer / 中国医学影像学杂志

ABSTRACT

Purpose To compare the diagnostic efficacy of 99Tcm-MIBI SPECT/CT tomography and SPECT imaging in evaluating neoadjuvant chemotherapy (NAC) in breast cancer,and to explore the clinical gain value of SPECT/CT tomography.Materials and Methods Forty-seven patients with biopsy pathologically confirmed breast cancer in General Hospital of Ningxia Medical University from 2010 to 2015 were retrospectively analyzed.99Tcm-MIBI SPECT/CT test was performed before NAC and 4-6 courses after.The patients were assigned into effective group and ineffective group based on the pathological response after NAC,the MIBI intake rate of tumors in the two groups was compared,and the efficiency of SPECT,CT and SPECT/CT in evaluating NAC were respectively calculated and compared.Results According to the postoperative pathological response,47 patients were divided into effective group (n=30) and ineffective group (n=17).In early phase,the T/N value of effective group and ineffective group was 1.46±0.58 and 1.10+0.48,respectively,with a statistically significant difference (t=2.185,P＜0.05).There was no significant difference between SPECT,CT and SPECT/CT in evaluating NAC efficacy and pathological response (P＞0.05).The sensitivity,specificity and accuracy of these three methods in evaluating NAC efficacy were respectively:80.0％,52.9％ and 70.2％ (SPECT);86.7％,70.6％ and 80.9％ (CT);92.3％,88.2％ and 89.4％ (SPECT/CT).There was a statistically significant difference between the specificity and accuracy of SPECT/CT tomography and SPECT imaging in evaluating NAC efficacy (x2=5.10 and 8.16,P＜0.05).Conclusion The intake rate of tumors can predict the sensitivity of NAC.The diagnostic efficacy of 99Tcm-MIBl SPECT/CT tomography is more effective than that of SPECT imaging in evaluating the efficacy of NAC in breast cancer.